MedTrace Logo

A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease

NCT03161912 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2481

Last updated 2022-11-14

No results posted yet for this study

Summary

AURIGA is designed to collect data from routine clinical practice on the effectiveness and utilization of intravitreal aflibercept in the treatment of visual impairment due to diabetic macular edema (DME) or macula edema secondary to retinal vein occlusion (RVO).

The primary objective of this observational study (OS) is to evaluate the effectiveness of intravitreal aflibercept in 4 cohorts (with/without prior treatment in DME or macular edema secondary to RVO) in each of the participating countries.

Additionally, utilization and treatment regimens in routine clinical practice will be described.

Health care resources and services as well as health out-comes related to vision loss will be evaluated based on information collected using the AURIGA patient questionnaires.

Conditions

  • Macular Edema

Interventions

DRUG

Aflibercept (Eylea, BAY86-5321)

As per the treating physicians discretion.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-24
Primary Completion
2021-09-14
Completion
2021-12-17

Countries

  • China
  • Egypt
  • France
  • Germany
  • Italy
  • Kuwait
  • Lebanon
  • Russia
  • Saudi Arabia
  • Taiwan
  • United Arab Emirates

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03161912 on ClinicalTrials.gov